Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System

13Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Tumors of the nervous system can be originated from several locations. They mostly have high mortality and morbidity rate. The emergence of resistance to chemotherapeutic agents is a hurdle in the treatment of patients. Long non-coding RNAs (lncRNAs) have been shown to influence the response of glioblastoma/glioma and neuroblastoma to chemotherapeutic agents. MALAT1, NEAT1, and H19 are among lncRNAs that affect the response of glioma/glioblastoma to chemotherapy. As well as that, NORAD, SNHG7, and SNHG16 have been shown to be involved in conferring this phenotype in neuroblastoma. Prior identification of expression amounts of certain lncRNAs would help in the better design of therapeutic regimens. In the current manuscript, we summarize the impact of lncRNAs on chemoresistance in glioma/glioblastoma and neuroblastoma.

Cite

CITATION STYLE

APA

Ghafouri-Fard, S., Agabalazadeh, A., Abak, A., Shoorei, H., Hassanzadeh Taheri, M. M., Taheri, M., & Sharifi, G. (2021, June 9). Role of Long Non-Coding RNAs in Conferring Resistance in Tumors of the Nervous System. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2021.670917

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free